Cargando…

Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage

OBJECTIVE: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a rare disease characterized by predominant upper lobe pulmonary fibrosis of unknown etiology. However, the prognosis of IPPFE has not been discussed. We investigated the clinical characteristics and prognostic factors of IPPFE and id...

Descripción completa

Detalles Bibliográficos
Autores principales: Shioya, Makoto, Otsuka, Mitsuo, Yamada, Gen, Umeda, Yasuaki, Ikeda, Kimiyuki, Nishikiori, Hirotaka, Kuronuma, Koji, Chiba, Hirofumi, Takahashi, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110001/
https://www.ncbi.nlm.nih.gov/pubmed/30186537
http://dx.doi.org/10.1155/2018/6043053
_version_ 1783350405660409856
author Shioya, Makoto
Otsuka, Mitsuo
Yamada, Gen
Umeda, Yasuaki
Ikeda, Kimiyuki
Nishikiori, Hirotaka
Kuronuma, Koji
Chiba, Hirofumi
Takahashi, Hiroki
author_facet Shioya, Makoto
Otsuka, Mitsuo
Yamada, Gen
Umeda, Yasuaki
Ikeda, Kimiyuki
Nishikiori, Hirotaka
Kuronuma, Koji
Chiba, Hirofumi
Takahashi, Hiroki
author_sort Shioya, Makoto
collection PubMed
description OBJECTIVE: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a rare disease characterized by predominant upper lobe pulmonary fibrosis of unknown etiology. However, the prognosis of IPPFE has not been discussed. We investigated the clinical characteristics and prognostic factors of IPPFE and idiopathic pulmonary fibrosis (IPF). METHODS: We performed a retrospective cohort study on 375 consecutive idiopathic interstitial pneumonia patients between April 2004 and December 2014. Among them, we diagnosed IPPFE and IPF patients using high-resolution computed tomography radiological criteria. RESULTS: Twenty-nine IPPFE patients (9 males, 20 females) and 67 IPF patients (54 males, 13 females) were enrolled. IPPFE patients were significantly more likely to be females and nonsmokers and had lower body mass index, lower values of predicted percentage of forced vital capacity (%FVC), and a higher residual volume-to-total lung capacity ratio than IPF patients. Survival analysis revealed that they had significantly poorer prognosis than IPF patients in GAP (gender, age, and physiology) stages II + III. %FVC and GAP index independently predict mortality in patients with IPPFE. CONCLUSIONS: Patients with IPPFE showed poorer prognosis in the advanced stage than patients with IPF. %FVC and GAP index are independent predictors of survival in patients with IPPFE.
format Online
Article
Text
id pubmed-6110001
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61100012018-09-05 Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage Shioya, Makoto Otsuka, Mitsuo Yamada, Gen Umeda, Yasuaki Ikeda, Kimiyuki Nishikiori, Hirotaka Kuronuma, Koji Chiba, Hirofumi Takahashi, Hiroki Can Respir J Research Article OBJECTIVE: Idiopathic pleuroparenchymal fibroelastosis (IPPFE) is a rare disease characterized by predominant upper lobe pulmonary fibrosis of unknown etiology. However, the prognosis of IPPFE has not been discussed. We investigated the clinical characteristics and prognostic factors of IPPFE and idiopathic pulmonary fibrosis (IPF). METHODS: We performed a retrospective cohort study on 375 consecutive idiopathic interstitial pneumonia patients between April 2004 and December 2014. Among them, we diagnosed IPPFE and IPF patients using high-resolution computed tomography radiological criteria. RESULTS: Twenty-nine IPPFE patients (9 males, 20 females) and 67 IPF patients (54 males, 13 females) were enrolled. IPPFE patients were significantly more likely to be females and nonsmokers and had lower body mass index, lower values of predicted percentage of forced vital capacity (%FVC), and a higher residual volume-to-total lung capacity ratio than IPF patients. Survival analysis revealed that they had significantly poorer prognosis than IPF patients in GAP (gender, age, and physiology) stages II + III. %FVC and GAP index independently predict mortality in patients with IPPFE. CONCLUSIONS: Patients with IPPFE showed poorer prognosis in the advanced stage than patients with IPF. %FVC and GAP index are independent predictors of survival in patients with IPPFE. Hindawi 2018-08-13 /pmc/articles/PMC6110001/ /pubmed/30186537 http://dx.doi.org/10.1155/2018/6043053 Text en Copyright © 2018 Makoto Shioya et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shioya, Makoto
Otsuka, Mitsuo
Yamada, Gen
Umeda, Yasuaki
Ikeda, Kimiyuki
Nishikiori, Hirotaka
Kuronuma, Koji
Chiba, Hirofumi
Takahashi, Hiroki
Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
title Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
title_full Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
title_fullStr Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
title_full_unstemmed Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
title_short Poorer Prognosis of Idiopathic Pleuroparenchymal Fibroelastosis Compared with Idiopathic Pulmonary Fibrosis in Advanced Stage
title_sort poorer prognosis of idiopathic pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis in advanced stage
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110001/
https://www.ncbi.nlm.nih.gov/pubmed/30186537
http://dx.doi.org/10.1155/2018/6043053
work_keys_str_mv AT shioyamakoto poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage
AT otsukamitsuo poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage
AT yamadagen poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage
AT umedayasuaki poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage
AT ikedakimiyuki poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage
AT nishikiorihirotaka poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage
AT kuronumakoji poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage
AT chibahirofumi poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage
AT takahashihiroki poorerprognosisofidiopathicpleuroparenchymalfibroelastosiscomparedwithidiopathicpulmonaryfibrosisinadvancedstage